课题基金 / 基金详情

项目摘要

项目成果

PAMELA ANN KOZLOWSKI的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To determine if Invaplex can adjuvant nasal DNA- or protein-based vaccines in nonhuman primates. Methods. Three groups of female rhesus macaques were nasally immunized on weeks 0, 4, and 8 with SIV gp130 protein and SHIV89.6 DNA. In Groups 2 and 3, the DNA/protein formulation was co-administered with 0.25mg and 0.5mg Invaplex, respectively. Five months later, all animals were nasally boosted with adenovirus vectors expressing SIV antigens (Ad-SIV). ELISA was used to quantitate SIV antibodies in serum and secretions. Intracellular cytokine staining was used to monitor T cell responses. Results: When compared to Group 1, animals in Group 3 demonstrated significantly greater SIV env-specific IgG in serum and IgA in secretions after the 3rd immunization. Systemic IgG and mucosal IgA to DNA-encoded antigens were also enhanced in Group 3. On wk12, Group 3 also demonstrated significantly greater frequencies of circulating SIV env-specific T cells secreting IFN-g. Group 2 exhibited intermediate responses that did not differ significantly from Group 1 or 3. Nasal boosting with Ad-SIV elevated SIV-specific antibodies in Group 3 to a significantly greater extent than Group 1. All groups had similar percentages of SIV env- and gag-specific T cells secreting IFN-g- and TNF-a-secreting in blood. Conclusions: Invaplex can adjuvant antibody and T cell responses to nasal protein immunogens in nonhuman primates. Invaplex can also enhance antibody generated after nasal DNA vaccination. Invaplex could potentially be used as an adjuvant for both nasal DNA and protein vaccines in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A NASAL DNA/PROTEIN VACCINE FOR ANTI-HIV ANTIBODY AND CTL
  • 批准号:
    8172999
  • 项目类别:
  • 资助金额:
    $6.18万
  • 财政年份:
    2010
  • 负责人:
    PAMELA ANN KOZLOWSKI
  • 依托单位:
NASAL DNA/PROTEIN VACCINE FOR ANTI-HIV ANTIBODY AND CTL
  • 批准号:
    7916232
  • 项目类别:
  • 资助金额:
    $1.43万
  • 财政年份:
    2009
  • 负责人:
    PAMELA ANN KOZLOWSKI
  • 依托单位:
Mucosal Antibodies
  • 批准号:
    7679566
  • 项目类别:
  • 资助金额:
    $18.38万
  • 财政年份:
    2008
  • 负责人:
    PAMELA ANN KOZLOWSKI
  • 依托单位:
NASAL VACCINES FOR PREVENTION OF HIV INFECTION
  • 批准号:
    7715456
  • 项目类别:
  • 资助金额:
    $23.79万
  • 财政年份:
    2008
  • 负责人:
    PAMELA ANN KOZLOWSKI
  • 依托单位:
海外基金